In a clinical trial expected to be completed next year, savolitinib is being administered to locally advanced or metastatic NSCLC patients with MET Exon 14 mutations (Clinicaltrials.gov identifier: NCT02897479). This evidence concerns the gene MET and non-small cell lung carcinoma.